As I stated prior to stock going ex div, my valuation is $2.50. This assumes earning steady and no more industry disruption. Indications are that this is occurring.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%